

Corporate Sponsored Presentations

Session Time (CST)	Abstract #/Title/Lead Author	Type/Session
Wednesday, December 6, 2023		
Wednesday, December 6, 2023 9:00AM-12:00PM	1544187 / Tucatinib SGNTUC-016 HER2CLIMB-02: Randomized, double-blind phase 3 trial of tucatinib and trastuzumab emtansine for previously treated HER2-positive metastatic breast cancer Lead Author: Hurvitz	Oral Presentation General Session 1
Wednesday, December 6, 2023 12:00-2:00PM	1573051 / Tucatinib SGNTUC-028 Trial in progress: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05) Lead Author: Hamilton	Poster Presentation Poster Session 1
Wednesday, December 6, 2023 12:00-2:00PM	1577368 / Disitamab Vedotin and Tucatinib Preclinical Disitamab vedotin, a clinical stage HER2-directed antibody-drug conjugate, shows potent antitumor activity as a monotherapy and in combination with tucatinib in preclinical breast cancer models Lead Author: Willis	Poster Presentation Poster Session 1

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

IST Presentations

Session Time (CST)	Abstract #/Title/Lead Author	Type/Session
Thursday, December 7, 2023		
Thursday, December 7, 2023 12:00-2:00PM	1579458 / Tucatinib A011801 (CompassHER2 RD) Trial in progress: Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer Lead Author: O'Sullivan	Poster Presentation Poster Session 3
Friday, December 8, 2023		
Friday, December 8, 2023 12:00-2:00PM	TBD / Tucatinib TUC-IST-2019-102201 (BRIDGET) Trial in progress: Secondary brain metastases prevention after isolated intracranial progression on trastuzumab/pertuzumab or T-DM1 in patients with advanced human epidermal growth factor receptor 2+ breast cancer with the addition of tucatinib (BRIDGET) Lead Author: Van Swearingen	Poster Presentation Poster Session 5

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.